Breast Cancer Survivors' Perceptions of Their Cardiovascular Care During Treatment With Anthracyclines or
Arnethea L Sutton1,2, Ashley Turner1, America Vijil1
1Department of Kinesiology and Health Sciences, Virginia Commonwealth University, Richmond, Virginia, USA.
Insights
Black and White breast cancer survivors had similar perceived care experiences, but differences emerged in family involvement and heart health information timing. Enhancing culturally sensitive communication is crucial for diverse patient populations.
Area of Science:
- Oncology
- Cardiology
- Health Disparities
Background:
- Cardiovascular disease (CVD) is a major cause of mortality in breast cancer survivors.
- Racial disparities in CVD outcomes exist between Black and White women.
Purpose of the Study:
- To assess breast cancer survivors' perceptions of heart health resources and communication.
- To evaluate racial differences in these perceptions during cardiotoxic therapy.
Main Methods:
- Qualitative analysis of semi-structured interviews with breast cancer survivors.
- Interviews focused on discussions of cancer treatment, CVD risk, and heart-healthy behaviors.
- Transcribed interviews were coded using Dedoose Qualitative Software.
Main Results:
- 17 survivors interviewed (9 White, 8 Black); most had high income and education.
- 88% recalled receiving heart health information; most received trastuzumab.
- Black survivors reported more positive experiences when family was involved; White survivors reported more positive overall experiences.
Conclusions:
- No striking differences in perceived care between Black and White survivors.
- Notable differences in community support and timing of heart health information were observed.
- Healthcare communication needs enhancement, particularly for culturally diverse populations.
Background:
Cardiovascular disease (CVD) is a leading cause of mortality among breast cancer survivors, and racial disparities exist between Black and White women. Therefore, the purpose of this study was to assess breast cancer survivors' perceptions of heart health resources and communication received during active treatment with potentially cardiotoxic therapies and to evaluate whether differences in perceptions are associated with race.
Methods:
This qualitative analysis included semi-structured interviews with breast cancer survivors who received potentially cardiotoxic treatment(s). Survivors were asked to recall conversations with their healthcare providers regarding cancer treatment, the risk of CVD during and following treatment, and discussions of heart healthy behaviors that could be employed during treatment. Audio recorded interviews were transcribed, and codes were developed using Dedoose Qualitative Software.
Results:
Of the 17 participants, 9 women were White and 8 were Black. A majority of participants were married (58.8%), reported an annual household income of at least $60,000, had a Bachelor's degree or higher (70.6%), and had a mastectomy (70.6%). Participants had an average age of 50.9 years (SD = 11.85). Approximately 88% (100% White women, 75% Black women) recalled receiving heart health information either prior to or during treatment. The majority also received trastuzumab (88.2%). Four themes were identified from the interviews. Key results showed that Black survivors were more likely to share positive experiences when their family members were a part of their treatment conversations and that White women were more likely to have positive experiences throughout their treatment.
Conclusions:
This qualitative analysis did not show striking differences in perceived care experiences between Black and White survivors. However, there were notable differences in community support, such as the inclusion of family members in treatment conversations and the receipt and timing of heart health information. Enhancing healthcare communication with a particular focus on culturally diverse populations is needed.
Related Concept Videos
01:21Cancer Survival Analysis
02:56Treatment Resistant Cancers
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:20Comparing the Survival Analysis of Two or More Groups
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...